OVERVIEW

The Intricacies of Immunotherapy and COVID-19: Strategies to Optimize Oncology Care is organized by Medscape, LLC.

CME / ABIM MOC / CE Released: 1/7/2021
Valid for credit through: 1/7/2022

Accreditation:
For Physicians
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

For Nurses
Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

Goal Statement:
The goal of this activity is to provide an overview of coronavirus disease 2019 (COVID-19) and how it relates to the patient with cancer being treated with immunotherapy, considerations on how to manage patients with cancer being treated with immunotherapy, and strategies that will help optimize care of the patient with cancer during the COVID-19 pandemic

Upon completion of this activity, participants will:
• Have increased knowledge regarding the differential diagnosis of EGIDs
? Effect of COVID-19 on patients with cancer receiving immunotherapy
? COVID-19 treatment options and potential impact of immunotherapy agents
• Have greater competence related to
? Strategies used to manage immunotherapy treatment during the COVID-19 pandemic